SMS Pharmaceuticals Limited (SMSPHARMA.BO)
INR 242.45
(2.08%)
INR 242.45
(2.08%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.21 Billion INR | 99.21% |
| 2022 | 593.89 Million INR | -50.73% |
| 2021 | 1.19 Billion INR | -3.92% |
| 2020 | 1.24 Billion INR | 47.1% |
| 2019 | 850.33 Million INR | -9.65% |
| 2018 | 935 Million INR | -2.11% |
| 2017 | 957.27 Million INR | 25.03% |
| 2016 | 762.45 Million INR | -17.23% |
| 2015 | 927.59 Million INR | -8.98% |
| 2014 | 1.02 Billion INR | 76.33% |
| 2013 | 586.71 Million INR | 141.64% |
| 2012 | -353.01 Million INR | -791.29% |
| 2011 | 140.57 Million INR | -49.46% |
| 2010 | 409.98 Million INR | -1.71% |
| 2009 | 400.14 Million INR | -3.42% |
| 2008 | 414.31 Million INR | -27.99% |
| 2007 | 575.37 Million INR | 11.69% |
| 2006 | 515.15 Million INR | 74.25% |
| 2005 | 268.5 Million INR | 20.53% |
| 2004 | 245.28 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 335.11 Million INR | -1.09% |
| 2023 Q1 | 266.96 Million INR | 15.05% |
| 2023 Q4 | 336.17 Million INR | 10.26% |
| 2023 FY | - INR | 99.21% |
| 2023 Q3 | 304.88 Million INR | 6.49% |
| 2023 Q2 | 286.31 Million INR | 7.25% |
| 2022 Q4 | 232.04 Million INR | 11.94% |
| 2022 FY | - INR | -50.73% |
| 2022 Q1 | -85 Thousand INR | 99.81% |
| 2022 Q2 | 141.74 Million INR | 166861.18% |
| 2022 Q3 | 207.28 Million INR | 46.24% |
| 2021 Q3 | 291.74 Million INR | -39.41% |
| 2021 FY | - INR | -3.92% |
| 2021 Q2 | 481.5 Million INR | 5.3% |
| 2021 Q1 | 457.25 Million INR | 10.19% |
| 2021 Q4 | -44.96 Million INR | -115.41% |
| 2020 Q1 | 222.54 Million INR | 34.55% |
| 2020 Q2 | 245.85 Million INR | 10.47% |
| 2020 FY | - INR | 47.1% |
| 2020 Q3 | 353.26 Million INR | 43.69% |
| 2020 Q4 | 414.96 Million INR | 17.47% |
| 2019 Q3 | 208.04 Million INR | -8.75% |
| 2019 FY | - INR | -9.65% |
| 2019 Q2 | 227.99 Million INR | -5.24% |
| 2019 Q1 | 240.58 Million INR | 50.55% |
| 2019 Q4 | 165.4 Million INR | -20.5% |
| 2018 Q1 | 240.66 Million INR | 0.0% |
| 2018 FY | - INR | -2.11% |
| 2018 Q4 | 159.81 Million INR | -38.97% |
| 2018 Q3 | 261.86 Million INR | -2.34% |
| 2018 Q2 | 268.13 Million INR | 11.41% |
| 2017 FY | - INR | 25.03% |
| 2016 FY | - INR | -17.23% |
| 2016 Q1 | 243.22 Million INR | 0.6% |
| 2016 Q2 | 290.19 Million INR | 19.31% |
| 2015 Q2 | 227.47 Million INR | 24.11% |
| 2015 FY | - INR | -8.98% |
| 2015 Q4 | 241.78 Million INR | -8.88% |
| 2015 Q3 | 265.34 Million INR | 16.65% |
| 2015 Q1 | 183.28 Million INR | -42.37% |
| 2014 Q3 | 345.56 Million INR | 111.88% |
| 2014 Q2 | 163.09 Million INR | -10.56% |
| 2014 FY | - INR | 76.33% |
| 2014 Q1 | 182.34 Million INR | -16.64% |
| 2014 Q4 | 318.04 Million INR | -7.96% |
| 2013 Q1 | 28.4 Million INR | -94.49% |
| 2013 Q4 | 218.75 Million INR | 8.53% |
| 2013 FY | - INR | 141.64% |
| 2013 Q3 | 201.54 Million INR | 63.9% |
| 2013 Q2 | 122.97 Million INR | 332.95% |
| 2012 Q4 | 515.01 Million INR | 895.45% |
| 2012 Q1 | 64.8 Million INR | -19.83% |
| 2012 Q2 | -72.13 Million INR | -211.31% |
| 2012 FY | - INR | -791.29% |
| 2012 Q3 | -64.74 Million INR | 10.25% |
| 2011 FY | - INR | -49.46% |
| 2011 Q4 | 80.84 Million INR | -21.44% |
| 2011 Q3 | 102.9 Million INR | 0.0% |
| 2010 FY | - INR | -1.71% |
| 2009 FY | - INR | -3.42% |
| 2008 FY | - INR | -27.99% |
| 2007 FY | - INR | 11.69% |
| 2006 FY | - INR | 74.25% |
| 2005 FY | - INR | 20.53% |
| 2004 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott India Limited | 16.97 Billion INR | 92.868% |
| Cipla Limited | 67.19 Billion INR | 98.198% |
| Gland Pharma Limited | 15.03 Billion INR | 91.946% |
| GlaxoSmithKline Pharmaceuticals Limited | 8.87 Billion INR | 86.354% |
| Kopran Limited | 890.24 Million INR | -36.007% |
| Marksans Pharma Limited | 4.58 Billion INR | 73.597% |
| NGL Fine-Chem Limited | 678.68 Million INR | -78.403% |
| Pfizer Limited | 8.23 Billion INR | 85.302% |
| Sanofi India Limited | 8.86 Billion INR | 86.346% |